At a glance
ClinicalIndex Comparison RecordN/ACompleted· 36 enrolled
Drug / intervention
Salsalate +3 moredrug
Likely dose
Salsalate 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects (Aim #2)
In Brief
A clinical study evaluating Salsalate, Carvedilol, and 2 other interventions for Hypertension and Diabetes. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The purpose of this study is to see if salsalate, an Nuclear factor-kappaB (NF-κB) mediated inflammation inhibitor, or carvedilol, an α- and β-blocker, will protect against free fatty acid induced hypertension, insulin resistance, endothelial dysfunction, inflammation and oxidative stress, and autonomic dysfunction in obese normotensive subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Diabetes
CountriesUnited States
CollaboratorsAmerican Diabetes Association
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
Primary CompletionMar 2011
First PostedApr 2015
TodayJul 2026
First PostedApr 2, 2015
Enrollment StartJul 1, 2009
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.3 years ago
Interventions
Salsalatedrug
Salsalate 750 mg
Carvediloldrug
Carvedilol 3.125 mg
Placebodrug
One tablet
Intralipid 20%drug
24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)